300 Antibody Diagnostic Test Kit (Antibody 300)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01646411|
Recruitment Status : Unknown
Verified July 2012 by The Plasma Source.
Recruitment status was: Enrolling by invitation
First Posted : July 20, 2012
Last Update Posted : July 20, 2012
|Condition or disease|
|Acute Bacterial Infections Acute Viral Infections|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Phase I Study for Positive IgM Antibody Detection in New Diagnostic Test Kit for for Acute Phase Infection|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||July 2013|
assorted acute infection
300 patients diagnosed with assorted acute infection.
- IgM greater than 1xcut off value [ Time Frame: Antibody value measured within seven days of specimen collection. ]
Elisa System positive results are greater than 1 times the cutoff. Negative less than 1x cutoff.
Prevalence of IGM in general mid-atlantic population is less than 10% of study population.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01646411
|United States, Pennsylvania|
|The Plasma Source|
|Southampton, Pennsylvania, United States, 18966|
|Study Director:||Jeffery Flieshman, M.S immunology|